|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 22, 2018 ) The in situ hybridization (ISH) market is segmented based on technology as, chromogenic in situ hybridization (CISH) and fluorescence in situ hybridization (FISH). The application segment is classified as, immunology, microbiology, cancer diagnostic, neuroscience, and infectious diseases. The end user is segment is classified as biotechnology/ pharmaceutical companies, academic & research institutes, molecular diagnostic labs.
In Situ Hybridization (ISH) is a process that utilizes labeled DNA or RNA probes to detect complementary DNA or RNA sites in a piece of tissue or in cytological preparation. This technique allows to gain temporary and three-dimensional information about gene expression and genetic site. The in-situ hybridization is similar to the blot hybridization.
The market for in situ hybridization (ISH) is expected to grow with a significant rate due to the factors such as, high prevalence of the cancer and infectious diseases, increase in the neuroscience studies, rise in the study and development of the neuroscience, immunology, microbiology and cytology. As the regulatory bodies are funding enormously for the healthcare industry, the players are receiving great opportunities to grow their market share in the biotechnological industry.
Request sample copy @ http://bit.ly/2IVdskH
List of Companies mentioned in this study -
1. Abbott.
2. Thermofisher Scientific, Inc.
3. PerkinElmer Inc.
4. Merck KGaA
5. F. Hoffmann-La Roche Ltd
6. Danaher
7. BioGenex
8. Bio SB
9. Exiqon (QIAGEN)
10. Oxford Gene Technology
The report provides a detailed overview on the industry including both qualitative and quantitative information. It provides overview and forecast of the global In Situ Hybridization (ISH) market based on, technology, application and end user. It also provides market size and forecast till 2025 for overall in situ hybridization (ISH) market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 countries globally along with current trend and opportunities prevailing in the region.
North America is anticipated as the largest market for in situ hybridization (ISH) market in the global scenario as the rise in the biological and clinical research for cancer diagnostic are been conducted by the various pharmaceutical and biotechnological companies. Filing for the patent right motivates the small companies to conduct more research for the various techniques that will give them more opportunities to expand their product portfolio and also to expand their geographic presence.
The report analyzes factors affecting market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the market in these regions.
Inquire Before Buying @ http://bit.ly/2J0QHfu
The report also includes the profiles of key In Situ Hybridization (ISH) manufacturing companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, products and services offered, financial information of last 3 years, key development in past five years. Some of the key players influencing the market are Abbott, ThermoFisher Scientific, Inc., PerkinElmer Inc., Merck KGaA, F. Hoffmann-La Roche Ltd, Danaher, BioGenex, Bio SB, Exiqon (QIAGEN), and Oxford Gene Technology.
The Insight Partners
Sameer Joshi
+1-646-491-9876
sam@theinsightpartners.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
